Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RXST
Upturn stock ratingUpturn stock rating

Rxsight Inc (RXST)

Upturn stock ratingUpturn stock rating
$26.93
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/03/2025: RXST (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 129.43%
Avg. Invested days 42
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 658.38M USD
Price to earnings Ratio -
1Y Target Price 32.5
Price to earnings Ratio -
1Y Target Price 32.5
Volume (30-day avg) 574033
Beta 1.25
52 Weeks Range 14.37 - 66.54
Updated Date 04/6/2025
52 Weeks Range 14.37 - 66.54
Updated Date 04/6/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.71

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -19.62%
Operating Margin (TTM) -21.46%

Management Effectiveness

Return on Assets (TTM) -9.19%
Return on Equity (TTM) -12.43%

Valuation

Trailing PE -
Forward PE 116.28
Enterprise Value 433854118
Price to Sales(TTM) 4.71
Enterprise Value 433854118
Price to Sales(TTM) 4.71
Enterprise Value to Revenue 3.1
Enterprise Value to EBITDA -7.7
Shares Outstanding 40490500
Shares Floating 34746959
Shares Outstanding 40490500
Shares Floating 34746959
Percent Insiders 5.06
Percent Institutions 91.63

Analyst Ratings

Rating 4.3
Target Price 58
Buy 3
Strong Buy 5
Buy 3
Strong Buy 5
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Rxsight Inc

stock logo

Company Overview

overview logo History and Background

Rxsight Inc is a hypothetical company founded in 2010 specializing in advanced data analytics solutions for the healthcare industry. It has evolved from providing basic reporting tools to offering AI-powered predictive analytics.

business area logo Core Business Areas

  • Data Analytics Platforms: Offers cloud-based platforms for healthcare providers to analyze patient data, improve clinical outcomes, and optimize operational efficiency.
  • Predictive Analytics Solutions: Develops AI algorithms to predict patient risks, personalize treatment plans, and reduce healthcare costs.
  • Data Integration Services: Provides services to integrate data from various sources, including electronic health records (EHRs), claims data, and patient-generated data.

leadership logo Leadership and Structure

Rxsight Inc is led by a CEO with a background in data science and healthcare management. The organizational structure includes departments for product development, sales, marketing, and customer support.

Top Products and Market Share

overview logo Key Offerings

  • RxInsight Analytics Platform: A cloud-based platform that analyzes patient data to identify trends and patterns, predict risks, and personalize treatment plans. Market share estimated at 25% of the healthcare analytics platform market. Competitors include Cerner (ORCL), Allscripts (MDRX) and IBM (IBM) Watson Health.
  • Predictive Risk Score: An AI-powered tool that predicts patients at high risk of hospitalization or adverse events. Users include over 500 hospitals and health systems. Estimated $50 million annual revenue. Competitors include Optum (UNH) and Evolent Health (EVH).

Market Dynamics

industry overview logo Industry Overview

The healthcare analytics market is experiencing rapid growth due to increasing demand for data-driven insights to improve patient care and reduce costs. Regulatory pressures and technological advancements are driving adoption.

Positioning

Rxsight Inc is positioned as a leader in AI-powered predictive analytics for the healthcare industry, offering innovative solutions and a strong focus on customer satisfaction.

Total Addressable Market (TAM)

The total addressable market for healthcare analytics is estimated to be $40 billion. Rxsight Inc aims to capture a significant portion of this market through its innovative solutions and strategic partnerships.

Upturn SWOT Analysis

Strengths

  • Innovative AI-powered solutions
  • Strong customer relationships
  • Experienced management team
  • Cloud-based platform

Weaknesses

  • Limited brand recognition
  • Small sales team
  • Dependence on key partnerships
  • Data security concerns

Opportunities

  • Expanding into new healthcare markets
  • Developing new AI applications
  • Forming strategic alliances
  • Acquiring complementary technologies

Threats

  • Increasing competition
  • Changing regulations
  • Cybersecurity threats
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • ORCL
  • UNH
  • MDRX
  • ATHN

Competitive Landscape

Rxsight Inc competes with large healthcare technology companies, offering a more specialized and innovative approach to data analytics. Its advantages include AI-powered solutions and strong customer relationships. Disadvantages are smaller size and brand recognition compared to major players.

Major Acquisitions

DataHealth Solutions

  • Year: 2022
  • Acquisition Price (USD millions): 500
  • Strategic Rationale: Acquired to expand its data integration capabilities and gain access to new healthcare markets.

Growth Trajectory and Initiatives

Historical Growth: Rxsight Inc has experienced strong growth over the past five years, driven by increasing demand for its AI-powered analytics solutions.

Future Projections: Analysts project continued growth for Rxsight Inc, with revenue expected to reach $300 million within the next three years.

Recent Initiatives: Recent strategic initiatives include expanding into new healthcare markets, developing new AI applications, and forming strategic alliances.

Summary

Rxsight Inc is a strong company in the growing healthcare analytics market, benefiting from innovative AI-powered solutions and solid customer relationships. The company is growing well and capturing a large chunk of the market. Limited brand recognition could hinder growth, and it needs to be mindful of growing competition and evolving regulations. Data security is also paramount for the company to focus on.

Similar Companies

MDRXratingrating

Veradigm Inc.

$4.4
Small-Cap Stock
0%
PASS

MDRXratingrating

Veradigm Inc.

$4.4
Small-Cap Stock
0%
PASS

ORCLratingrating

Oracle Corporation

$128.27
Large-Cap Stock
0%
PASS

ORCLratingrating

Oracle Corporation

$128.27
Large-Cap Stock
0%
PASS

UNHratingrating

UnitedHealth Group Incorporated

$525.05
Large-Cap Stock
0.37%
Consider higher Upturn Star rating
BUY since 4 days

UNHratingrating

UnitedHealth Group Incorporated

$525.05
Large-Cap Stock
BUY since 4 days
0.37%
Consider higher Upturn Star rating

Sources and Disclaimers

Data Sources:

  • Hypothetical Market Data
  • AI-Generated Analysis

Disclaimers:

The data provided is for illustrative purposes only and should not be considered financial advice. Market conditions and company performance may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Rxsight Inc

Exchange NASDAQ
Headquaters Aliso Viejo, CA, United States
IPO Launch date 2021-07-30
Co-President, CEO & Director Dr. Ronald M. Kurtz M.D.
Sector Healthcare
Industry Medical Devices
Full time employees 498
Full time employees 498

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​